| Literature DB >> 27571370 |
Amalie Kai Bentzen1, Andrea Marion Marquard2, Rikke Lyngaa1, Sunil Kumar Saini1, Sofie Ramskov1, Marco Donia3,4, Lina Such1, Andrew J S Furness5,6, Nicholas McGranahan5,7, Rachel Rosenthal5,7, Per Thor Straten3,8, Zoltan Szallasi2, Inge Marie Svane3,4, Charles Swanton5,7, Sergio A Quezada5,6, Søren Nyboe Jakobsen1,9, Aron Charles Eklund2, Sine Reker Hadrup1.
Abstract
Identification of the peptides recognized by individual T cells is important for understanding and treating immune-related diseases. Current cytometry-based approaches are limited to the simultaneous screening of 10-100 distinct T-cell specificities in one sample. Here we use peptide-major histocompatibility complex (MHC) multimers labeled with individual DNA barcodes to screen >1,000 peptide specificities in a single sample, and detect low-frequency CD8 T cells specific for virus- or cancer-restricted antigens. When analyzing T-cell recognition of shared melanoma antigens before and after adoptive cell therapy in melanoma patients, we observe a greater number of melanoma-specific T-cell populations compared with cytometry-based approaches. Furthermore, we detect neoepitope-specific T cells in tumor-infiltrating lymphocytes and peripheral blood from patients with non-small cell lung cancer. Barcode-labeled pMHC multimers enable the combination of functional T-cell analysis with large-scale epitope recognition profiling for the characterization of T-cell recognition in various diseases, including in small clinical samples.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27571370 DOI: 10.1038/nbt.3662
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908